Background/Aims: As a suitable test to screen for Alzheimer's disease (AD) or mild cognitive impairment (MCI), studies to validate the Chinese version of Addenbrooke's Cognitive Examination-Revised (ACE-R) are rare. Methods: A total of 151 subjects were recruited and the neuropsychological assessments were employed. One-way analysis of variance and Bonferroni correction were used to compare scores of different psychometric scales. Intraclass correlation coefficient (ICC) and Cronbach's coefficient α were used to evaluate the reliability of psychometric scales. The validity of ACE-R to screen for mild AD and amnestic subtype of MCI (a-MCI) was assessed by receiver operating characteristic (ROC) curves. Results: The Chinese ACE-R had good reliability (inter-rater ICC = 0.994; test-retest ICC = 0.967) as well as reliable internal consistency (Cronbach's coefficient α = 0.859). With its cutoff of 67/68, the sensitivity (0.920) and specificity (0.857) were lower than for the Mini-Mental State Examination (MMSE) cutoff (sensitivity 1.000 and specificity 0.937) to screen for mild AD. However, the sensitivity of ACE-R to screen for a-MCI was superior to the MMSE with a cutoff of 85/86. The specificity of ACE-R was lower than that of the MMSE to screen for a-MCI. The area under the ROC curve of ACE-R was much larger than that of the MMSE (0.836 and 0.751) for detecting a-MCI rather than mild AD. Conclusion: The Chinese ACE-R is a reliable assessment tool for cognitive impairment. It is more sensitive and accurate in screening for a-MCI rather than for AD compared to the MMSE.

Keywords:
Alzheimer’s disease, Addenbrooke’s Cognitive Examination-Revised, Mild cognitive impairment, Mini-Mental State Examination, Chinese, Screening
1.
Naylor MD, Karlawish JH, Arnold SE, et al: Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement 2012;8:445-452.
2.
Petersen RC, Roberts RO, Knopman DS, et al: Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-1455.
3.
Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
4.
Petersen RC, Morris JC: Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005;62:1160-1163.
5.
Ellison JM: A 60-year-old woman with mild memory impairment: review of mild cognitive impairment. JAMA 2008;300:1566-1574.
6.
Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
7.
Ahmed S, de Jager C, Wilcock G: A comparison of screening tools for the assessment of mild cognitive impairment: preliminary findings. Neurocase 2012;18:336-351.
8.
Mauri M, Sinforiani E, Zucchella C, et al: Progression to dementia in a population with amnestic mild cognitive impairment: clinical variables associated with conversion. Funct Neurol 2012;27:49-54.
9.
Mioshi E, Dawson K, Mitchell J, et al: The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21:1078-1085.
10.
Lischka AR, Mendelsohn M, Overend T, et al: A systematic review of screening tools for predicting the development of dementia. Can J Aging 2012;31:295-311.
11.
Lonie JA, Tierney KM, Ebmeier KP: Screening for mild cognitive impairment: a systematic review. Int J Geriatr Psychiatry 2009;24:902-915.
12.
Ferreira IS, Simões MR, Marôco J: The Addenbrooke's Cognitive Examination Revised as a potential screening test for elderly drivers. Accid Anal Prev 2012;49:278-286.
13.
Kwak YT, Yang Y, Kim GW: Korean Addenbrooke's Cognitive Examination Revised (K-ACER) for differential diagnosis of Alzheimer's disease and subcortical ischemic vascular dementia. Geriatr Gerontol Int 2010;10:295-301.
14.
Konstantinopoulou E, Kosmidis MH, Ioannidis P, et al: Adaptation of Addenbrooke's Cognitive Examination-Revised for the Greek population. Eur J Neurol 2011;18:442-447.
15.
Terpening Z, Cordato NJ, Hepner IJ, et al: Utility of the Addenbrooke's Cognitive Examination-Revised for the diagnosis of dementia syndromes. Australas J Ageing 2011;30:113-118.
16.
Torralva T, Roca M, Gleichgerrcht E, et al: Validation of the Spanish version of the Addenbrooke's Cognitive Examination-Revised (ACE-R). Neurologia 2011;26:351-356.
17.
Alexopoulos P, Ebert A, Richter-Schmidinger T, et al: Validation of the German revised Addenbrooke's cognitive examination for detecting mild cognitive impairment, mild dementia in Alzheimer's disease and frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2010;29:448-456.
18.
Dos Santos Kawata KH, Hashimoto R, Nishio Y, et al: A validation study of the Japanese version of the Addenbrooke's Cognitive Examination-Revised. Dement Geriatr Cogn Dis Extra 2012;2:29-37.
19.
Alexopoulos P, Greim B, Nadler K, et al: Validation of the Addenbrooke's cognitive examination for detecting early Alzheimer's disease and mild vascular dementia in a German population. Dement Geriatr Cogn Disord 2006;22:385-391.
20.
Pigliautile M, Ricci M, Mioshi E, et al: Validation study of the Italian Addenbrooke's Cognitive Examination Revised in a young-old and old-old population. Dement Geriatr Cogn Disord 2011;32:301-307.
21.
McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
22.
Guo Q, Zhao Q, Chen M, et al: A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord 2009;23:253-259.
23.
Roberts RO, Geda YE, Knopman DS, et al: The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69.
24.
Macklin EA, Blacker D, Hyman BT, et al: Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 2013;36:475-486.
25.
Pagonabarraga J, Gómez-Ansón B, Rotger R, et al: Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease. Dement Geriatr Cogn Disord 2012;34:312-318.
26.
Roberts RO, Knopman DS, Geda YE, et al: Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement 2013, DOI: 10.1016/j.jalz.2013.01.001.
27.
Chan KW, Lee TM, Siu AM, et al: Effects of chronic ketamine use on frontal and medial temporal cognition. Addict Behav 2013;38:2128-2132.
28.
Mortimer JA, Ding D, Borenstein AR, et al: Changes in brain volume and cognition in a randomized trial of exercise and social interaction in a community-based sample of non-demented Chinese elders. J Alzheimers Dis 2012;30:757-766.
29.
Zhao S, Guo C, Wang M, et al: A clinical memory battery for screening for amnestic mild cognitive impairment in an elderly Chinese population. J Clin Neurosci 2011;18:774-779.
30.
Carter SF, Caine D, Burns A, et al: Staging of the cognitive decline in Alzheimer's disease: insights from a detailed neuropsychological investigation of mild cognitive impairment and mild Alzheimer's disease. Int J Geriatr Psychiatry 2012;27:423-432.
31.
Yoshida H, Terada S, Honda H, et al: Validation of the revised Addenbrooke's Cognitive Examination (ACE-R) for detecting mild cognitive impairment and dementia in a Japanese population. Int Psychogeriatr 2012;24:28-37.
32.
Crawford S, Whitnall L, Robertson J, et al: A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination-Revised in the diagnosis of dementia. Int J Geriatr Psychiatry 2012;27:659-669.
33.
Raimondi C, Gleichgerrcht E, Richly P, et al: The Spanish version of the Addenbrooke's Cognitive Examination - Revised (ACE-R) in subcortical ischemic vascular dementia. J Neurol Sci 2012;322:228-231.
34.
Budson AE, Solomon PR: New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist. Pract Neurol 2012;12:88-96.
35.
Lunnon K, Sattlecker M, Furney SJ, et al: A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis 2013;33:737-753.
36.
Zhang N, Song X, Zhang Y: Combining structural brain changes improves the prediction of Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2012;33:318-326.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.